XML 94 R77.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Total revenues $ 376,072 $ 196,542 $ 59,606
Cost of sales 36,695 19,128 4,987
Research and development 77,051 76,420 110,575
Selling, general and administrative 274,553 229,391 185,145
Total operating expenses 388,299 324,939 300,707
Loss from operations (12,227) (128,397) (241,101)
Interest income 8,897 16,126 12,517
Interest expense (12,083) (27,168) (29,712)
Other income (expense), net 443 47 (731)
Provision for income taxes 1,171 647 3,113
Net loss (16,141) (140,039) (262,140)
Reportable Segment      
Segment Reporting Information [Line Items]      
Total revenues 376,072 196,542 59,606
Cost of sales 32,028 17,169 4,237
Research and development compensation and personnel-related expenses 39,779 39,216 44,613
Selling, general and administrative 274,033 228,908 184,628
Other segment expenses 24,408 20,014 22,607
Total operating expenses 388,299 324,939 300,707
Loss from operations (12,227) (128,397) (241,101)
Interest income 8,897 16,126 12,517
Interest expense (12,083) (27,168) (29,712)
Other income (expense), net 443 47 (731)
Provision for income taxes 1,171 647 3,113
Net loss (16,141) (140,039) (262,140)
Topical roflumilast program costs | Reportable Segment      
Segment Reporting Information [Line Items]      
Research and development 10,938 5,210 35,607
Topical JAK inhibitor program costs | Reportable Segment      
Segment Reporting Information [Line Items]      
Research and development 741 2,945 3,334
Other early-stage programs costs | Reportable Segment      
Segment Reporting Information [Line Items]      
Research and development $ 6,372 $ 11,477 $ 5,681